Sunday Poster Session
Category: Colon

Vanessa Avalone, MD
Boston Medical Center
Boston, MA
Anal squamous cell carcinoma (ASCC) is a rare malignancy with increasing incidence and mortality rates in the United States. The treatment of ASCC with chemoradiation remains standard of care. However, with next generation sequencing (NGS) and cell free methylated DNA (cfDNA; Galleri test), novel targeted therapies are being investigated. Risk factors for ASCC include human papillomavirus (HPV), tobacco use, and immunocompromised states. Hidradenitis Suppurativa (HS) is a chronic, relapsing inflammatory skin condition that has been associated with cutaneous and mucosal SCC arising from HS lesions. Malignancy risk increases with HS severity, HPV presence, and duration and location in the ano-genital region. We present a case of ASCC in a HS patient whose diagnosis was aided by precision medicine tools.
A 67-year-old non-smoker male with long-standing HS affecting his axilla and perineal area, presented to Primacy Care Clinic with several months of peri-anal discomfort and a swollen inguinal lymph node (LN). Biopsy of the LN showed HPV-associated, metastatic p16-positive SCC (Figure 1) without a known primary tumor. Subsequent cfDNA methylation screening predicted cancer signals originating from the head/neck and anus regions. Colonoscopy was performed, which revealed a mass at the dentate line (Figure 1) without involvement of the anal canal. NGS was performed on LN tissue with the molecular profile summarized in table 1, and PD-L1 tumor proportion score was highly positive with 80% suggesting tentatively actionable targets of the PIK3K/AKT/MTOR pathways and immunotherapy. Initially, the patient received chemoradiation with 5FU/ Mitomycin and XRT with an excellent response.

